Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB103 versus placebo in necrotizing soft tissue infections
2018-001125-15Phase 3Completed
- Sponsor
- Atox Bio
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in necrotizing skin infection (NSTI) comparing AB103 with Placebo (2 arms). Primary endpoint: Clinical composite success endpoint (NICCE). Started May 2018; status: completed.
02
Drugs
reltecimod
03
Conditions
necrotizing skin infection (NSTI)
Beyond the preview
Go deeper on 2018-001125-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001125-15.